ASCO 2013: PD-1 and PD-L1 inhibitors – the next-gen immunotherapies.
By James Wade, Lead Analyst
6 June 2013
I am the lead analyst for our pharma company analysis at Datamonitor Healthcare. I studied Neuroscience at the Universit...
Read full bio
ASCO 2013 saw Bristol-Myers Squibb, Merck & Co, and Roche present updated and new data on their PD-1 and PD-L1 inhibitors. The data presented show that the competition between these three drugs could be a lot closer than initially expected. Melanoma appears to be the front-running indication at present, but developers all have their sights set on bigger commercial targets.
Presentations and discussions surrounding the new wave of cancer immunotherapies were a key highlight of the 2013 American Society of Clinical Oncology annual meeting (ASCO 2013). Programmed death 1 (PD-1) and its ligands have emerged as a key target for developers looking for the next generation of immunotherapies. This follows the success of Bristol-Myers Squibb’s cytotoxic T-lymphocyte antigen-4 (CTLA-4) inhibitor Yervoy (ipilimumab).
This also features a tabular summary of PD-1 and PD-L1 targeting drugs in development and the trial landscape.